Background. The multifunctional receptor LRP1 controls expression, activity and trafficking of the PDGF receptor-b in vascular smooth muscle cells (VSMC). LRP1 is also a receptor for TGFb1 and is required for TGFb mediated inhibition of cell proliferation. Methods and Principal Findings. We show that loss of LRP1 in VSMC (smLRP 2 ) in vivo results in a Marfan-like syndrome with nuclear accumulation of phosphorylated Smad2/3, disruption of elastic layers, tortuous aorta, and increased expression of the TGFb target genes thrombospondin-1 (TSP1) and PDGFRb in the vascular wall. Treatment of smLRP1 2 animals with the PPARc agonist rosiglitazone abolished nuclear pSmad accumulation, reversed the Marfan-like phenotype, and markedly reduced smooth muscle proliferation, fibrosis and atherosclerosis independent of plasma cholesterol levels. Conclusions and Significance. Our findings are consistent with an activation of TGFb signals in the LRP1-deficient vascular wall. LRP1 may function as an integrator of proliferative and anti-proliferative signals that control physiological mechanisms common to the pathogenesis of Marfan syndrome and atherosclerosis, and this is essential for maintaining vascular wall integrity.
INTRODUCTION
Cholesterol-induced atherosclerosis is a major cause of morbidity and mortality in Western societies. In the liver, the low-density lipoprotein (LDL) receptor functions in concert with another LDL receptor family member, the LDL receptor-related protein 1 (LRP1), in removing cholesterol carrying lipoprotein particles from the bloodstream. However, in the smooth muscle cells of the artery wall LRP1 acts through a different, cholesterol-independent mechanism in the maintenance of vascular wall integrity and atherosclerosis prevention, which relies in part on the ability of LRP1 to regulate the activity and subcellular trafficking of the PDGFRb [1] [2] [3] . SmLRP 2 mice that lack LRP1 in vascular smooth muscle cells show thickening of the muscular layer and greatly increased susceptibility to atherosclerotic lesion development, even at low plasma cholesterol levels. On a high cholesterol diet, lesion development and progression is dramatically accelerated, resulting in the occlusion of major arteries within 2 months of cholesterol feeding. Pharmacologic inhibition of PDGFRb signaling reduced both lesion progression and smooth muscle over-proliferation, suggesting that the abnormal activation of PDGFRb is at least in part responsible for the accelerated lesion development and progression [1] .
On the other hand, the characteristic disruption of elastic layers, elongation of the aortas and aneurysms are hallmarks of Marfan syndrome (MFS) [4, 5] , an autosomal dominant genetic disease. MFS is caused by loss of function mutations in fibrillin-1, a microfibrillar protein that coats the surface of elastic fibers where it binds and immobilizes the TGFb large latency complex (LLC) [6] . Haploinsufficiency of fibrillin-1 [7, 8] markedly changes the extracellular targeting, sequestration and turnover of latent TGFb, resulting in pronounced activation of the growth factor and the signaling pathway [4, 5, 9] . A phenotypically similar Marfanlike syndrome is caused by loss of function mutations in TGFb receptors 1 or 2 [10] [11] [12] , which nevertheless result in a paradoxical activation of the pathway and nuclear accumulation of pSmad2 [10] . Thus, abnormal activation of TGFb signaling appears to be a common feature of Marfan and Marfan-like disorders.
Recently, LRP1 was reported to be identical to TGFbR(V), which is coexpressed together with TGFb receptors I, II and III. LRP1/TGFbR(V) is required for mediating the growth inhibitory response of TGFb, in conjunction with Smad2/3 signaling through TGFbR(I) and (II) [13, 14] . TGFb1 can induce the expression of connective tissue growth factor (CTGF), PDGF-B and PDGF receptors [15] [16] [17] [18] [19] . Activation of a PDGF/PDGFR autocrine loop by TGFb mediates epithelial-mesenchymal transition and constitutes a crucial mechanism that enhances tumor metastasis [20] and the malignancy of gliomas [21] . All of these proteins are not only ligands for LRP1, they also promote smooth muscle cell proliferation [16, 22] . Furthermore, TSP1, another ligand for LRP1 and a TGFb target gene [23] , directly mediates the conversion of latent TGFb to the active form [24, 25] and TSP1 binding to an LRP1/calreticulin complex regulates cell adhesion [26] . Thus, LRP1 is tightly involved in the control of growth regulating signaling processes that involve TGFb, PDGF, and their receptors. This prompted us to investigate, whether abnormal activation of TGFb signaling could be responsible for the striking disruption of the elastic fiber network, fibrosis, and accelerated atherosclerotic lesion development in the vascular wall of smLRP 2 mice [1] .
RESULTS
Activation of TGFb signaling in LRP1-deficient VSMC ) in their VSMC ( Figure 1 ). Expression of TSP-1, a direct TGFb1 target gene, was strikingly increased in LRP 2 compared to LPR + aortas (Panels a and b), whereas total TGFb1 immunoreactivity was slightly reduced (Panels c and d), consistent with an increased activation and turnover of matrix-associated TGFb.
TGFb1 and other TGFb family members, as well as angiotensin II are prominent inducers of Smad2-dependent target gene transcription, resulting in collagen deposition and disruption of the elastic layers in the vascular wall [27, 28] . Prominent accumulation of nuclear phosphorylated Smad2/3 (pSmad2/3) was found in VSMC in the absence of LRP1 (Panels e and f). This effect was specific for Smad2, which is the target of TGFb signals, but not for Smad1, which responds to signals elicited by bone morphogenic proteins (BMPs). pSmad1 was not significantly elevated in the absence of LRP1 (Panels g and h). These findings, taken together with the molecular properties of LRP1, make it likely that TGFb signaling in VSMC is indeed selectively increased in the absence of LRP1.
Rosiglitazone reduces TGFb signals in vitro and in vivo
PPARc agonists of the thiazolidinedione class have been reported to inhibit TGFb signaling, CTGF expression and fibrosis [29, 30] , and they also can reduce atherosclerosis [31] . We therefore decided to test, whether activation of PPARc by rosiglitazone, a compound of this class that is in clinical use, might result in reduced nuclear accumulation of pSmad2 and suppression of atherosclerosis in mice lacking LRP1. We first examined the effect of rosiglitazone on PDGFRb and pSmad2/3 levels in cultured cells in vitro. While TGFb1 only moderately elevated PDGFRb expression in vitro, it markedly increased pSmad2/3 levels in cultured human VSMC and in murine fibroblasts. This increase was significantly blunted when the cells were pretreated with rosiglitazone ( Figure 2 ).
To test, whether rosiglitazone was able to correct the abnormal accumulation of pSmad2/3 levels and activation of PDGFRb signaling in smLRP deficient animals in vivo, we fed smLRP + and smLRP 2 animals a cholesterol-rich diet that either contained or did not contain rosiglitazone for 5 weeks (Figure 3 ). Aortic extracts were prepared as described earlier [1] abolished the increased nuclear pSmad2/3, overexpression of PDGFRb, and the increased pErk1/2 levels in the smLRP 2 animals (Panels b, e, h). As had been shown previously using the tyrosine kinase inhibitor Gleevec [1] , rosiglitazone treatment also considerably improved the integrity of the elastic layers (Panel C). Rosiglitazone prevents atherosclerosis in smLRP 2 mice Thiazolidinediones have been reported to protect male LDLRdeficient mice from developing atherosclerotic lesions [31] , coinciding with reductions in gelatinase and TNFa expression. To test whether blockade of the increased Smad activation by rosiglitazone would also reduce the marked atherosclerosis in the smLRP 2 mice, we quantitatively examined the aortas from the atherogenic diet-fed mice. Atherosclerotic lesion areas were significantly reduced in the presence of the PPARc agonist ( Figure 4A and C), and the striking thickening and fibrosis of the LRP deficient vessel wall was almost completely abolished ( Figure 4B ). Importantly, these changes were not caused by or secondary to any effect of rosiglitazone on the plasma lipoprotein profile, triglyceride or cholesterol levels ( Figure 4D-F) .
DISCUSSION
The findings we have presented here reveal a novel mechanism by which the multifunctional receptor LRP1 functions as an integrator of two distinct cellular signaling pathways in the vascular wall. They also suggest a functional relationship between the molecular events that underlie MFS, the formation of aneurysms and atherosclerosis. Our results show that LRP1 controls Smad2/3-as well as PDGF-dependent signaling in VSMC in a coordinated fashion and by distinct mechanisms.
LRP1 is a target of PDGFRb-dependent Src kinase activation [2, 32] and we showed earlier that loss of LRP1 expression in VSMCs results in increased PDGFRb expression and activation [1, 3] . In the present study we have demonstrated, that loss of LRP1 expression also results in increased Smad2/3-dependent signaling in VSMCs. A potent inducer of Smad2 phosphorylation and nuclear translocation is TGFb [33] . Moreover, induction of PDGF as well as PDGFRb expression in response to TGFb stimulation has been recognized as an important component of epithelial-mesenchymal transition, a process that underlies metastasis of some tumors [20] and increases the aggressiveness of others [21] . Our results show that increased pSmad2/3 signaling in the LRP1-deficient vascular wall results in increased PDGFRb expression and activation, making it likely that TGFb is directly involved. Furthermore, LRP1/TGFbR(V), can directly bind TGFb1 [13] , as well as enter into a complex with TGFbR(I) [34] . By binding and endocytosis of the active growth factor and also by sequestering TGFbR(I) away from TGFbR(II), LRP1 is in a central position where it can suppress the normal mode of TGFb signaling and Smad2/3 activation through the TGFbR(I)/R(II) complex. In addition, LRP1 mediates the endocytosis of TSP1 as well as several matrix metalloproteinases (MMP) from the extracellular space [35] [36] [37] , and TSP1 as well as active MMP2 and MMP9 levels are increased in smLRP deficient aortas (Figure 1, and [1] ). TSP1 and MMPs potently and independently activate TGFb1 [24, 25, 38] . Loss of smLRP would thus be predicted to activate TGFb/Smad signaling in VSCM by multiple independent mechanisms, and this is consistent with the dramatically increased nuclear pSmad2/3 levels in smLRP 2 aortas (Figure 1 ). The resulting disruption of elastic layers, vascular fibrosis, elongation and distension of the aorta, and high incidence of aortic aneurysms directly support the pivotal role of TGFb signaling in the pathogenesis of MFS and reveal LRP1 as a critical regulator of this pathway in vivo. As such, LRP1 could conceivably contribute as a genetic modifier to the variable severity of expression of MFS in humans.
We have further demonstrated the importance of TGFb signaling through pharmacological intervention and reversal of the smLRP 2 phenotype with the PPARc agonist rosiglitazone. Activation of PPARc with thiazolidinediones potently inhibits TGFb signaling in vitro and in vivo [29, 39, 40] . The striking effect of rosiglitazone on the nuclear accumulation of pSmad2/3 and the near complete reversal of the aortic wall thickening and fibrosis, and prevention of atherosclerotic lesion progression confirm the central importance of TGFb pathway activation for this phenotype. PPARc agonists might thus complement and enhance the potential therapeutic use of the angiotensin II type 1 receptor blocker Losartan in the treatment of MFS [27] .
Increased susceptibility to atherosclerosis is not a part of the MFS complex, but a striking feature of smLRP 2 mice [1] . Likewise, PPARc agonists are only partially effective against dietinduced atherosclerosis in LDLR deficient mice when LRP1 is functional [31] . By contrast, we have shown that rosiglitazone (this study) as well as the PDGFR tyrosine kinase inhibitor Gleevec [1] are highly potent in protecting smLRP 2 mice from atherosclerosis. Our findings thus suggest that abnormal activation of PDGFRb signaling, which has so far not been reported in MFS, is the major mediator of the increased atherosclerosis in the smLRP 2 mice, and that increased PDGFRb activity is brought about by two independent and synergistic mechanisms. First, activation of Smad/TGFb signals in the absence of LRP1 results in the disruption of elastic layers and a tortuous aorta [1] , as well as increased expression of PDGF receptors (Figure 2 and 3 ) [15, 20, 41] . However, since LRP1 also controls PDGFRb activity and recycling at the level of the plasma membrane [3] , loss of LRP1 in smooth muscle cells also results in a greatly increased mitogenic response, VSMC proliferation and the promotion of atherosclerotic lesion formation. This second event is prevented in MFS by the presence of LRP1, which suppresses the abnormal PDGFRb activation through a posttranslational mechanism [3] . Thus, rosiglitazone (as a Smad/TGFb antagonist) and Gleevec (as a PDGFRb inhibitor) act at different steps in a linear sequence of events ( Figure 5 ) that result in a Marfan-like syndrome and culminate in extensive atherosclerosis in smLRP 2 artery walls. Nevertheless, blockade of PDGFRb signaling alone by administration of Gleevec was sufficient to reduce atherosclerotic lesion progression, as well as vascular wall thickness, in smLRP 2 mice [1] , suggesting that signaling through this pathway is necessary for elastic layer disruption and wall thickening. This raises the possibility that PDGFRb signaling may be activated to some extent in the Marfan vessel wall, or alternatively the mere suppression of its baseline activity may be sufficient to normalize the vessel wall thickening that is initiated by increased TGFb activity. Consistent with an important role of PDGFRb in vascular thickening is a recent report that showed transphosphorylation of a truncated PDGFRb induced by the Angiotensin II type 1 receptor (AT1) [42] , which can also activate Smad2-dependent signals independent of TGFb [28] . AT1 is inhibited by Losartan, a drug that also reduced wall thickening in a mouse model of Marfan syndrome [27] . Taken together, these findings indicate a critical role for Smad2-and AT1-dependent signaling mechanisms in Marfan and Marfan-like syndromes and identify PDGFRb as another important component of the pathogenic mechanism. Our findings also suggest that rosiglitazone, a clinically approved antidiabetic drug, may be useful for the treatment of vasculopathies that are caused by increased TGFb signaling, e.g. Marfan syndrome, as well as for the supportive treatment of certain malignancies, such as malignant glioblastomas [43] .
MATERIALS AND METHODS

Transgenic mice and diets
Homozygous LDL receptor (LDLR 2/2 ) animals LRP deficient in vascular smooth muscle cells (SM22-Cre + ;LRP flox/flox ;LDLR 2/2 , referred to as smLRP 2 or LRP 2 ) have been described previously [1] and were maintained on Teklad 6% (w/w) Mouse/Rat Diet 7002 from Harlan Teklad Premier Laboratory Diets (Madison, WI). Six weeks prior to sacrifice, 3-6 months old LRP 2 and littermate controls (LRP flox/flox ;LDLR 2/2 , noted LRP + ) were placed on a high-fat/high-cholesterol (Paigen) diet containing (21% (w/w) milk fat, 1.25% (w/w) cholesterol, 0.5% (w/w) cholic acid) and where indicated, the PPARc agonist rosiglitazone (AdvantiaH, GlaxoSmithKline, 25mg/kg/day) was mixed into the diet. All animals used in the experiments were age and sex matched as closely as possible. All animal experiments were conducted according to procedures approved by the institutional Animal Care and Use Committee (IACUC) at UT Southwestern.
Whole Aorta staining
After 4% paraformaldehyde cardiac perfusion, the whole aortas of animals from the different treated groups were carefully dissected from the heart to the iliac bifurcation. The vessels were rinsed in PBS and dissected to remove connective tissue and attached fat. The vessels were opened longitudinally and stained for lipids with Sudan IV. Atherosclerosis in the aortas was measured by quantitation of Sudan IV-positive lesions as described [44] . Whole mount preparations of the vessels were photographed and digitized. Sudan IV-positive lesions were delineated and analyzed using NIH Image software (NIH, Bethesda, Maryland, USA).
Histology
Aortic tissue was fixed over night with 4% paraformaldehyde and embedded in paraffin. Longitudinal and transverse sections (10 mm thick) were stained with hematoxylin-eosin under standard conditions.
Immunofluorescence microscopy
Anesthetized wt and LRP KO mice were perfused through the left cardiac ventricle with warmed Hank's balanced salt solution (20 mM Hepes, pH 7.3) followed by the same solution containing 4% (w/v) paraformaldehyde. Aortas were removed and divided into small pieces. The tissue was immersion-fixed for an additional hour followed by treatment with a mixture of 60% (v/v) methanol, 10% (v/v) glacial acetic acid, 30% (v/v) inhibisol (1,1,1-trichloroethane) for 24 hours. Tissues were then embedded in paraffin. Paraffin sections (5 mm thick) were dewaxed in three changes of xylene (10 minutes each) and rehydrated in PBS. Sections were washed with 50 mM NH 4 Cl in PBS for 30 minutes and blocked by incubation for 1 h in TBS (10 mM Tris-HCl, pH 9.0, 150 mM NaCl) containing 10% (v/v) normal goat serum and 1% (w/v) bovine serum albumin. Samples were then incubated overnight at 4C with rabbit antiserum raised against pSmad2 (1:200 dilution), PDGFRb (1:100 dilution), phospho-Erk (1:100 dilution), or preimmune rabbit serum (1:100 dilution). Sections were washed three times in TBS containing 0.1% bovine serum albumin, and bound primary antibody was detected by incubation for 2 h with Alexa-Fluor 488-conjugated goat antirabbit IgG (10 mg/ml, Molecular Probes, Eugene, OR). The tissues slides were washed three times in TBS containing 0.1% bovine serum albumin, rinsed with water, and mounted using Fluorescence Mounting Medium (DakoCytomation). Images were taken using a Leica TCS SP confocal microscope.
Lipid and Lipoprotein analyses
At sacrifice, blood was collected by cardiac puncture and plasma was analyzed by FPLC on a Superose 6 column (Sigma Chemical Co.). Plasma and liver cholesterol content was determined spectrofluorimetrically as described previously [45] .
Western blotting
MEF LRP deficient cells were seeded in 100 mm dishes (300 000 cells/dish) and grown to confluency in 10 ml DMEM supple- mented with 10% (v/v) fetal calf serum and antibiotics. MEF LRP deficient cells were either left untreated or treated for the indicated times with the PPARc agonist rosiglitazone under reduced serum conditions (0.2% fetal calf serum), followed by stimulation with recombinant human TGFb1 (200 pM) for 0, 1.5, 3 or 6 hours. Whole cell lysates were then prepared as described previously [1] , subjected to SDS polyacrylamide gel electrophoresis, transferred to poly(vinylidene) fluoride (PVDF) membranes (Millipore), and blotted for phospho-Smad2/3 or PDGF receptor-b using specific antibodies directed against PDGF receptor-b and phosphoSmad2/3 (S465/467), respectively (all from Upstate Biotechnology Incorporated, Lake Placid, NY). Proteins were detected using enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech Inc, Piscataway, NJ).
